John L Werth
Overview
Explore the profile of John L Werth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
2018
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fowler J, Sugarman J, Sher L, Zang C, Werth J, Myers D, et al.
Dermatol Ther (Heidelb)
. 2023 Feb;
13(4):951-960.
PMID: 36811773
Introduction: Using data from three clinical trials, the effect of crisaborole treatment on sleep outcomes for pediatric patients with atopic dermatitis (AD) and their families was examined. Methods: This analysis...
2.
Geng B, Hebert A, Takiya L, Miller L, Werth J, Zang C, et al.
Dermatol Ther (Heidelb)
. 2021 Sep;
11(5):1679.
PMID: 34550541
No abstract available.
3.
Spergel J, Blaiss M, Lio P, Kessel A, Cantrell W, Takiya L, et al.
Allergy Asthma Proc
. 2021 Sep;
42(5):425-431.
PMID: 34474712
Crisaborole is a nonsteroidal anti-inflammatory phosphodiesterase 4 inhibitor that is approved for the treatment of patients with mild-to-moderate atopic dermatitis (AD); however, the efficacy and safety of crisaborole in patients...
4.
Geng B, Hebert A, Takiya L, Miller L, Werth J, Zang C, et al.
Dermatol Ther (Heidelb)
. 2021 Aug;
11(5):1667-1678.
PMID: 34379285
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring long-term treatment. Crisaborole significantly improved global AD signs and symptoms in 28-day phase 3 studies of patients aged ...
5.
Schlessinger J, Shepard J, Gower R, Su J, Lynde C, Cha A, et al.
Am J Clin Dermatol
. 2020 Mar;
21(2):275-284.
PMID: 32212104
Background: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). Objectives: The aim of this study was to evaluate the safety, effectiveness,...
6.
Bissonnette R, Pavel A, Diaz A, Werth J, Zang C, Vranic I, et al.
J Allergy Clin Immunol
. 2019 Aug;
144(5):1274-1289.
PMID: 31419544
Background: Crisaborole ointment 2% is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). The mechanism of action of crisaborole and its effects on lesional measures...
7.
Brody M, Liu E, Di J, Lu M, Margolin R, Werth J, et al.
J Alzheimers Dis
. 2016 Sep;
54(4):1509-1519.
PMID: 27589523
Background: Bapineuzumab, a humanized monoclonal antibody, targets amyloid-β (Aβ1-40/1 -42) that is believed to play a key role in the pathogenesis of Alzheimer disease (AD). Objectives: To assess the effects...
8.
Roth T, Zammit G, Lankford A, Mayleben D, Stern T, Pitman V, et al.
Sleep
. 2010 Apr;
33(4):449-58.
PMID: 20394313
Study Objectives: Explore characteristics of nonrestorative sleep (NRS) in prospectively defined subgroups of individuals with NRS symptoms, investigate whether NRS can occur independently of difficulties initiating and maintaining sleep (DIS/DMS),...
9.
Corrigan B, Feltner D, Ouellet D, Werth J, Moton A, Gibson G
Br J Clin Pharmacol
. 2009 Aug;
68(2):174-80.
PMID: 19694735
Aims: To investigate the pharmacokinetics and safety of PD 0200390 in healthy subjects and subjects with renal impairment (RI) and to examine the relationship between oral and renal PD 0200390...
10.
Miller R, Ewy W, Corrigan B, Ouellet D, Hermann D, Kowalski K, et al.
J Pharmacokinet Pharmacodyn
. 2005 Nov;
32(2):185-97.
PMID: 16283534
The idea of model-based drug development championed by Lewis Sheiner, in which pharmacostatistical models of drug efficacy and safety are developed from preclinical and available clinical data, offers a quantitative...